Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
CRBU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $3.00
Previous CloseN/A
Volume598.80K
Average Volume (3M)977.77K
Market Cap
$217.91M
Enterprise Value-$40.88M
Total Cash (Recent Filing)$208.47M
Total Debt (Recent Filing)$26.22M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Nov 11, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding93,123,240
10 Day Avg. Volume1,385,237
30 Day Avg. Volume977,775
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.19
Enterprise Value/Revenue-4.12
Enterprise Value/Gross Profit-5.19
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$4.40Price Target Upside81.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPresentation of initial dose escalation results from the Phase 1 CaMMouflage trial, which is evaluating CB-011 in r/r MM, is another anticipated catalyst.
Financial OutlookCRBU ended the period with $183.9mm in cash and equivalents, expected to fund future developments.
Product DevelopmentCB-010's allogeneic nature could provide a distinct advantage and potentially become the preferred agent if confirmatory cohort results are similar to Yescarta's.
Bears Say
Market CompetitionCRBU announced in-line results and provided enrollment updates across its pipeline.
Regulatory EnvironmentCRBU remains exposed to changes at CBER and Dr. Prasad’s view of accelerated approval in oncology.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.66 and its highest was $3.00 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $217.91M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Nov 11, 2025 which is in 33 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Aug 12, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.052.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.35.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 93,123,240 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went up 8.939%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
Caribou Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.40 (81.07% Upside)
$4.40 (81.07% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 73.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.51%
12-Months-Change
Fundamentals
Return on Equity
-68.93%
Trailing 12-Months
Asset Growth
-40.77%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$4.40
▲(81.07% Upside)
Technical Analysis
Sangamo Biosciences
―
Cellectis SA
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
Ownership Overview
8.15% Insiders
9.35% Mutual Funds
15.42% Other Institutional Investors
60.35% Public Companies and
Individual Investors